Howe & Rusling Inc. Purchases 292 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Howe & Rusling Inc. increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,036 shares of the pharmaceutical company’s stock after purchasing an additional 292 shares during the period. Howe & Rusling Inc.’s holdings in Vertex Pharmaceuticals were worth $3,270,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of VRTX. Concord Wealth Partners lifted its holdings in Vertex Pharmaceuticals by 52.9% in the 4th quarter. Concord Wealth Partners now owns 1,156 shares of the pharmaceutical company’s stock worth $470,000 after purchasing an additional 400 shares in the last quarter. Mach 1 Financial Group LLC bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $735,000. Beck Bode LLC increased its holdings in shares of Vertex Pharmaceuticals by 316.0% in the fourth quarter. Beck Bode LLC now owns 28,875 shares of the pharmaceutical company’s stock worth $11,749,000 after purchasing an additional 21,934 shares during the last quarter. Sivik Global Healthcare LLC lifted its position in shares of Vertex Pharmaceuticals by 0.3% in the fourth quarter. Sivik Global Healthcare LLC now owns 12,500 shares of the pharmaceutical company’s stock worth $5,086,000 after buying an additional 40 shares in the last quarter. Finally, Hartford Funds Management Co LLC grew its holdings in Vertex Pharmaceuticals by 7.7% during the 4th quarter. Hartford Funds Management Co LLC now owns 890 shares of the pharmaceutical company’s stock valued at $362,000 after buying an additional 64 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Insider Activity

In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 3,222 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,354,013.28. Following the completion of the sale, the executive vice president now owns 74,364 shares in the company, valued at approximately $31,250,727.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 354 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the transaction, the executive vice president now directly owns 55,804 shares in the company, valued at approximately $23,755,762.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Amit Sachdev sold 3,222 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the sale, the executive vice president now directly owns 74,364 shares in the company, valued at approximately $31,250,727.36. The disclosure for this sale can be found here. Insiders sold 12,381 shares of company stock worth $5,203,249 over the last three months. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX traded up $9.33 during trading hours on Wednesday, reaching $402.14. The company’s stock had a trading volume of 1,236,091 shares, compared to its average volume of 1,221,349. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.99 and a quick ratio of 3.78. Vertex Pharmaceuticals Incorporated has a 1-year low of $320.01 and a 1-year high of $448.40. The company’s 50-day moving average is $410.52 and its two-hundred day moving average is $399.52. The firm has a market capitalization of $103.94 billion, a price-to-earnings ratio of 28.28, a P/E/G ratio of 1.87 and a beta of 0.35.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, topping the consensus estimate of $3.85 by $0.35. The company had revenue of $2.52 billion during the quarter, compared to analyst estimates of $2.50 billion. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. During the same period in the previous year, the business earned $3.33 EPS. On average, equities analysts predict that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current year.

Analyst Upgrades and Downgrades

VRTX has been the subject of a number of research reports. Sanford C. Bernstein downgraded Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Friday, February 2nd. Truist Financial upped their target price on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Evercore ISI raised Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 target price on the stock in a research report on Thursday, April 11th. Royal Bank of Canada boosted their price objective on shares of Vertex Pharmaceuticals from $397.00 to $420.00 and gave the company a “sector perform” rating in a research report on Tuesday, February 6th. Finally, Maxim Group cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Three analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $429.45.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.